Abstracts support continued Acthar coverage in NS setting, says Piper Jaffray Piper Jaffray said abstracts for the upcoming American Society of Nephrology show data for Acthar in nephrotic syndrome, or NS. Piper views the data as added evidence of efficacy for the drug in the NS setting, making it more likely that payors will continue to cover Acthar in this setting. The firm sees a possible near-term trading opportunity in shares of Questcor, but keeps a Neutral rating on the name.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.